4-((3-((4-(2-(4-Hydroxyphenyl)propan-2-yl)phenoxy)methyl)benzyl)oxy)benzimidamide (BIIL-260) is a potent, orally active leukotriene B4 (LTB4) receptor antagonist with anti-inflammatory activity; it is the active metabolite of the prodrug BIIL-284. BIIL-260 interacts reversibly and competitively with the LTB4 receptor, exhibiting high affinity for LTB4 receptors on isolated human neutrophil membranes (Ki = 1.7 nM).